Competing in the Global Cancer Diagnostics Market, 2019: Supplier Shares, Segment Forecasts for Major Tumor Markers & Growth Opportunities - ResearchAndMarkets.com

DUBLIN--()--The "Competing in the Global Cancer Diagnostics Market: Supplier Shares, Segment Forecasts for Major Tumor Markers, Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

This new the author comprehensive seven-country study identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

The new report contains 1,200 pages, 450 tables, and provides test volume and sales forecasts for major tumor markers, as well as supplier sales and shares by test, market segment and country. Available by country and section.

Highlights

  • Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five years
  • Examines trends in the U.S., Europe and Japan
  • Reviews current and emerging tumor markers
  • Analyzes applications of emerging diagnostic technologies
  • Forecasts sales of major tumor markers by country and market segment
  • Profiles leading market players and potential entrants
  • Suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • UK
  • USA

Market Segmentation Analysis

  • Sales and market shares of major suppliers, by individual tumor marker and country.
  • Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:
  • Hospitals
  • Commercial/Private Laboratories
  • Physician Offices/Group Practices
  • Cancer Clinics
  • Ambulatory Care Centers
  • Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
  • Cancer statistics, etiology and recent developments in the U.S., Japan and five major European countries.

Current and Emerging Products

  • Review of over 200 current and emerging tumor markers, including:
  • Biochemical Markers
  • Oncogenes
  • Growth Factors
  • Hormones
  • Colony Stimulating Factors
  • Lymphokines
  • Immunohistochemical Stains, and others.
  • Analysis of major immunoassay analyzers used for tumor marker testing, including their operating characteristics, features and selling prices.

Technology Review

  • Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and their potential applications for tumor marker testing.
  • Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
  • Extensive listings of over 500 companies, universities and research centers developing new tumor markers and detection technologies.

Competitive Assessments

  • Extensive strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

Worldwide Market Overview

  • Estimated universe of laboratories performing tumor marker testing by country.
  • Five-year test volume and sales projections by country.

Business Opportunities and Strategic Recommendations

  • Specific new product development opportunities with potentially significant market appeal during the next five years.
  • Design criteria for new products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.

Companies Mentioned

  • Abbott
  • Affymetrix
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Diamedix
  • DiaSorin
  • Eiken Chemical
  • Elitech Group
  • Enzo Biochem
  • Fujirebio
  • Grifols
  • GSK Biologicals
  • Hologic
  • Leica Biosystems
  • Lonza
  • Ortho-Clinical Diagnostics
  • PerkinElmer
  • Qiagen
  • Roche
  • Scienion
  • Sequenom
  • SeraCare
  • Siemens Healthineers
  • Takara Bio
  • Thermo Fisher
  • Wako

For more information about this report visit https://www.researchandmarkets.com/r/l78v7z

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900